A 35-year-old woman is diagnosed with follicular lymphoma (grade 1–2) with stage III disease. She is asymptomatic with normal LDH. What is the preferred first-line treatment?

Explanation

## First-Line Management of Indolent Follicular Lymphoma **Key Point:** For asymptomatic, early-stage or advanced indolent follicular lymphoma, rituximab monotherapy or observation (watch-and-wait) are both acceptable first-line approaches; chemotherapy is not mandatory upfront. ### Rationale for Rituximab Monotherapy or Observation **High-Yield:** Follicular lymphoma is an indolent disease with a median survival of 10–15 years. Many patients remain stable without immediate treatment; when intervention is needed, rituximab monotherapy is preferred over chemotherapy because: 1. **Rituximab alone is effective** — Induces durable remissions (median PFS ~2–3 years) without chemotherapy toxicity. 2. **Observation is safe** — Asymptomatic patients with normal LDH can be safely monitored; ~20% never require treatment. 3. **Chemotherapy is reserved** — For symptomatic disease, bulky disease, or rituximab-refractory patients. | Scenario | First-Line Approach | Rationale | | --- | --- | --- | | **Asymptomatic, stage I–II** | Observation ± rituximab | Indolent course; no survival benefit to early treatment | | **Asymptomatic, stage III–IV** | Rituximab monotherapy OR observation | Rituximab delays progression; observation is also safe | | **Symptomatic or bulky disease** | Rituximab ± chemotherapy (R-CHOP/R-CVP) | Symptoms warrant intervention | | **Relapsed/refractory** | Bendamustine + rituximab, or novel agents | Chemotherapy for resistant disease | **Clinical Pearl:** The "watch-and-wait" strategy is supported by randomized trials (e.g., RESORT trial) showing no OS difference between immediate rituximab and deferred treatment in asymptomatic patients. This preserves chemotherapy for later use. ### Why Chemotherapy Is Not First-Line **Mnemonic:** **FILO = Follicular Indolent, Limited Obligation** — avoid upfront chemotherapy in asymptomatic disease. - Rituximab monotherapy achieves similar PFS to R-CHOP without alkylating agent exposure. - Chemotherapy increases risk of secondary malignancy and myelodysplasia in long-term survivors. - Deferring chemotherapy allows use of novel agents (e.g., PI3K inhibitors, BTK inhibitors) at progression. **Warning:** Do not confuse indolent follicular lymphoma (grade 1–2) with grade 3b, which behaves more aggressively and may warrant R-CHOP upfront. [cite:Harrison 21e Ch 104]